Results 91 to 100 of about 1,651 (200)

The Integration of Astatine-211 as Potential Radiotheranostics in Personalized Cancer Treatment [PDF]

open access: yes
Astatine-211 (At-211) belongs to the group of alpha radioisotopes used for targeted radiotherapy (TAT). The advantages of astatine-211 over other alpha emitters are its higher linear energy transfer - LET (~100 keV/μm) and short-range tissue penetration ...
Apostolova, Paulina   +1 more
core  

The “Actual Retail Price” of Equity Trades

open access: yesThe Journal of Finance, Volume 80, Issue 5, Page 2507-2541, October 2025.
ABSTRACT We compare execution quality of six brokerage accounts across five brokers by generating a sample of 85,000 simultaneous market orders. Commission levels and payment for order flow (PFOF) differ across our accounts. We find that execution prices vary significantly across brokers: the mean account‐level round‐trip cost ranges from 0.07% to 0.46%
CHRISTOPHER SCHWARZ   +4 more
wiley   +1 more source

Norepinephrine transporter–targeted cancer theranostics — new horizons [PDF]

open access: yes
In the evolving landscape of precision oncology, this review delineates the role of radiopharmaceuticals targeting the norepinephrine transporter (NET), with a particular focus on the current clinical application of 123I-MIBG diagnostic imaging and 131I ...
Chen, Xinyu   +4 more
core   +1 more source

The role of long non‐coding RNAs in lung cancer metastasis: Molecular mechanisms, pathogenesis and clinical implications

open access: yesClinical and Translational Medicine, Volume 15, Issue 8, August 2025.
LncRNAs are localized in cytosol, nucleus, other sub‐nuclear compartments, and exosomes in the cell, and play significant role in lung cancer dissemination based on their localizations. LncRNAs have emerged as promising biomarkers for both early detection and prognosis.
Musaffe Tuna   +2 more
wiley   +1 more source

Gold Nanostars: A Novel Platform for Developing 211At-Labeled Agents for Targeted Alpha-Particle Therapy

open access: yesInternational Journal of Nanomedicine, 2021
Yang Liu,1 Zhengyuan Zhou,2 Yutian Feng,2 Xiao-Guang Zhao,2 Ganesan Vaidyanathan,2 Michael R Zalutsky,1,2 Tuan Vo-Dinh1,3,4 1Department of Biomedical Engineering, Duke University, Durham, NC, 27708, USA; 2Department of Radiology, Duke University Medical ...
Liu Y   +6 more
doaj  

Biological intratumoral therapy for the high-grade glioma part II: vector- and cell-based therapies and radioimmunotherapy. [PDF]

open access: yes, 2019
Management of high-grade gliomas (HGGs) remains a complex challenge with an overall poor prognosis despite aggressive multimodal treatment. New translational research has focused on maximizing tumor cell eradication through improved tumor cell targeting ...
Achrol, Achal Singh   +4 more
core   +2 more sources

PARP1-targeted alpha therapy enhances target expression

open access: yesEJNMMI Research
Graphical ...
Hasan Babazada   +8 more
doaj   +1 more source

All that glitters is not gold: high uptake on PSMA PET in non-prostate cancers does not mean that treatment with [<177Lu]Lu-PSMA-radioligand will be successful [PDF]

open access: yes
Background The main objective is to discuss why treatment of non-prostate cancers with [177Lu]Lu-PSMAradioligand achieved only low tumor dose in most published cases, despite high uptake on PSMA PET.
Bogsrud, Trond   +9 more
core   +1 more source

Qualitative and quantitative imaging of alpha‐emitting radiopharmaceuticals

open access: yesiRADIOLOGY
Targeted alpha (α) therapy (TAT) is an emerging therapeutic strategy for cancer treatment. To evaluate the safety and efficacy of targeted α‐therapy, the biodistribution and internal radiation dose of α‐emitting radionuclides should be determined.
Lan Wang   +7 more
doaj   +1 more source

Data from Biodistributions, Myelosuppression, and Toxicities in Mice Treated with an Anti-CD45 Antibody Labeled with the α-Emitting Radionuclides Bismuth-213 or Astatine-211

open access: gold, 2023
Hirohisa Nakamae   +10 more
openalex   +1 more source

Home - About - Disclaimer - Privacy